

Certificate of Analysis for NR-52185

Acinetobacter baumannii, Strain MRSN 11224

Catalog No. NR-52185

This reagent is the tangible property of the U.S. Government.

Product Description:

Acinetobacter baumannii (A. baumannii), strain MRSN 11224 was isolated in 2012 from a human wound in the United States as part of a global surveillance program. A. baumannii, strain MRSN 11224 was deposited as sensitive to colistin and resistant to amikacin, ceftazidime, ciprofloxacin, ceftriaxone, cefepime, gentamicin, imipenem, trimethoprim/sulfamethoxazole, levofloxacin, meropenem, tobramycin, tetracycline and ampicillin/sulbactam. NR-52185 lot 70038538 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70038538 Manufacturing Date: 28AUG2020

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth and cream (Figure 1)
Growth at 44°C ± 2°C¹ 1 day in an aerobic atmosphere on Tryptic Soy agar	Growth	Growth
Motility Remel™ Motility Test Medium w/TTC Indicator for 1 day at 37°C in an aerobic atmosphere	Report results	Non-motile
VITEK® MS (MALDI-TOF)	A. baumannii	A. baumannii (99.9%)
Antibiotic Susceptibility Profile ^{2,3}		
Amikacin	Resistant	Resistant (64 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (48 µg/mL)
Cefepime	Resistant	Resistant (> 256 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Resistant	Resistant (≥ 4 µg/mL)
Colistin	Sensitive	Sensitive (≤ 0.25 μg/mL)
Gentamicin	Resistant	Resistant (≥ 16 µg/mL)
Imipenem	Resistant	Resistant (> 8 μg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 μg/mL)
Meropenem	Resistant	Resistant (≥ 8 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (> 4 μg/mL)
Tobramycin	Resistant	Resistant (24 µg/mL)
Tetracycline	Resistant	Resistant (> 256 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1400 base pairs)	≥ 99% sequence identity to A. baumannii, strain MRSN 11224 (GenBank: VHHL01000097.1)	99.8% sequence identity to A. baumannii, strain MRSN 11224 (GenBank: VHHL01000097.1)
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898



Certificate of Analysis for NR-52185

TEST	SPECIFICATIONS	RESULTS
Viability	Growth	Growth

¹Growth at 44°C differentiates A. baumannii from A. calcoaceticus and A. pittii, which do not grow at 44°C.

Figure 1: Colony Morphology



/Heather Couch/ <u>Heather Couch</u>

28 APR 2021

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Tel: 800-359-7370 Fax: 703-365-2898

²Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

³Antibiotic susceptibility was tested using a combination of VITEK®2 GN82, Sensititre™ GNX2F AST and E-test strips.